GILD241122C74000
- 22.55
- 0.000.00%
Gilead Sciences Newsroom
26 Analysts Assess Gilead Sciences: What You Need To Know
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Analyst Ratings
Express News | Gilead : RBC Raises Target Price to $84 From $81
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
US Manufacturing Index Rises To 43, Highest Since 2020
Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead on Pace for Largest Percent Decrease Since February -- Data Talk
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
Express News | Biotechnology etf plunges! Pharmaceutical stocks collectively decline, with the United States Secretary of Health and Human Services nominee raising market concerns.
Express News | Gilead Sciences Inc - No Treatment-Related Serious Adverse Events Reported for Livdelzi
Express News | Gilead Sciences Inc - Livdelzi Shows 81% Efficacy in Phase 3 Assure Study
Express News | Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences Initiated at Outperform by Wolfe Research
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.